MidWestOne Financial Group Inc. Buys 232 Shares of IQVIA Holdings Inc. (NYSE:IQV)

MidWestOne Financial Group Inc. lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,786 shares of the medical research company’s stock after purchasing an additional 232 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in IQVIA were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. PGGM Investments boosted its position in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after buying an additional 4,326 shares during the period. Simplify Asset Management Inc. boosted its position in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the period. Raymond James & Associates boosted its position in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the period. Versor Investments LP acquired a new stake in IQVIA during the 3rd quarter worth approximately $1,328,000. Finally, Gradient Investments LLC boosted its position in IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares during the period. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent analyst reports. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. BTIG Research dropped their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 4th. Finally, Truist Financial lowered their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

Shares of NYSE:IQV opened at $203.31 on Wednesday. The company’s 50-day moving average is $214.57 and its 200 day moving average is $224.96. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $36.90 billion, a P/E ratio of 26.68, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.